RxDoctor Payments Data

Denise Force

Adult Health · Middletown, NJNPI 1770067522

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $69,696 of the $71,200 with a category attached, or 97.9%. Medtronic accounts for 98.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $44,229 and has fallen 53.8% since, to $20,455 in 2025. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$71,200in general payments, 2019–2025

Across 205 payments — averaging $347.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$70K
  • Novo Nordisk$218
  • GSK$201
  • Abbott$191
  • Corcept Therapeutics$158
  • Lilly USA, LLC$110
  • plus $557 from 16 others

What the payments were for

  • Speaking & faculty fees$69,69698%
  • Food & beverage$1,5032%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,200 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$40,708
Medicare patients
160
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$32,409
FarxigaDapagliflozin Propanediol24$26,021
MounjaroTirzepatide19$23,186
JardianceEmpagliflozin13$19,534
TrulicityDulaglutide11$18,300
JanuviaSitagliptin Phosphate15$13,555
MyrbetriqMirabegron12$5,932
SynthroidLevothyroxine Sodium28$2,946
Nano 2nd Gen Pen NeedlePen Needle, Diabetic16$2,020
Levothyroxine Sodium89$1,188
Fluticasone Propionate29$426
Alendronate Sodium29$403
Atorvastatin Calcium37$388
Metformin Hcl ErMetformin Hcl38$364
Metformin Hcl38$345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$110$41,48630 claims
Novo NordiskOzempic$218$32,40923 claims
AstraZenecaFarxiga$14$26,02124 claims
Boehringer IngelheimJardiance$28$19,53413 claims
AbbVieSynthroid$65$2,94628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Middletown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →